About ortHOTalk

Rigor asks: can you believe the result? Every paper starts from a prior based on its study design (a randomized trial or meta-analysis can exclude more bias than a retrospective series, so it starts higher) and carries a ceiling from the same table that no execution quality removes: a cross-sectional study cannot establish temporality, a cadaveric construct cannot speak to patient outcomes. The starting points are deliberately narrow and the ceilings deliberately wide, because execution is supposed to decide, not the label. Journal tier is worth a few points at most and decays to nothing once most of the methods have been read directly, so reputation is never counted twice.

The appraisal then moves the score on the things a journal club would check: loss to follow-up, an a-priori power calculation, allocation concealment, blinded outcome assessment, intention-to-treat analysis, prospective registration, crossover between the arms as randomised, whether the headline result is actually the study's primary outcome, and whether follow-up was long enough for the clinical question being asked. For significant dichotomous results we also compute the fragility index (how many patients would have to flip outcomes for significance to vanish) and flag the classic tell where more patients were lost to follow-up than the result can absorb. Meta-analyses and systematic reviews are further judged on what they pool (a meta-analysis of retrospective series is not Level I evidence), whether publication bias was assessed, and the AMSTAR-2 critical domains: one critical failure caps rigor at 64, and two or more cap it at 42. I² and the review's reported GRADE certainty do not receive conduct points: they adjust ranking credibility once, separately. Author royalties on the device under study cost a little; a sponsor-run analysis on top of those conflicts costs more.

When a paper simply doesn't report something, that scores as neutral, never negative: absence of evidence about the methods is not evidence of bad methods. A property test now holds the whole model to that contract: observing a strength can only raise a score, observing a defect can only lower it, and silence moves nothing. An earlier build shrank the summed appraisal toward the design prior as the appraisal thinned, and because that multiplier grew as criteria were added it could let an observed defect raise the score, so it was removed in favour of one constant. A thinly appraised paper now sits near its prior simply because few criteria moved it. Sparseness widens the uncertainty band and subtracts the excess uncertainty from the live rank, and a paper read on under 60% of its applicable criteria has its clinical importance held at 85, so it cannot win the week on ignorance.

Clinical importance asks: even if it's true, does it matter? Every paper starts from the same flat 45, and the dominant adjustment is where the confidence interval falls once it is measured in units of the minimal clinically important difference (MCID) of the outcome instrument. Orthopedic outcomes are dominated by patient-reported scores with published MCIDs, and a statistically significant three-point change on a scale whose MCID is ten is noise wearing a p-value. Every extracted effect now carries its printed unit, so a risk difference of 0.05 cannot be mistaken for five percentage points. Risk ratios and odds ratios are converted with their own formulas using the control-arm rate. Hazard ratios decline rather than being treated as risks unless time-specific baseline survival is available.

Clinical importance is deliberately not built on how strongly the authors phrase their conclusion, because that is exactly what spin inflates: 44.8% of orthopedic trials with a non-significant primary outcome contain spin, and spun papers are cited more often. The authors calling their own work practice-changing is worth 0 points. What the data show is worth up to 25.

Beyond that, patient-important outcomes score above radiographic surrogates, reporting harms earns a small one, and a weak or missing comparator costs points. A trial that screened four thousand patients to randomise sixty has answered the question for a sliver of the people you treat, however cleanly it answered it, and that narrowness costs points as well. Guideline collision and novelty now live on a separate editorial-priority axis: they may change what should be read this week without pretending the treatment effect is larger. Because those signals overlap, they share a budget capped at 24.

Every design carries an absolute clinical-importance ceiling no execution removes. A well-run propensity-matched registry cohort stops at 72, a flawless cadaveric study at 40, and even a flawless multicentre trial at 92: the top of the scale is reserved for synthesis, because a clinical-importance score of 99 means a finding that overturns a guideline or becomes one, and a Strong recommendation needs two or more concordant high-quality studies. None of this is a statement that a given paper is poor: it says a single study cannot on its own close a question, and that a bench study has demonstrated a mechanical property rather than a patient benefit. The week's open questions are handed to the appraisal, which records which one a paper answers if it answers any; that record earns nothing in the score.

A small recency decay comes off the top so this week's papers outrank last month's leftovers: 1.5 points a week past the first, and never more than 12 in total. A retraction zeroes the score outright; nothing else can.

Here is what that produces. Rigor runs across, clinical importance runs up, and every point on one contour scores the same heat. These are the worked archetypes the scoring code is tested against, plotted at the coordinates it actually emits.

Two things in that picture are the whole argument. The contours bend up to the left, so the same heat costs far more clinical importance when the methods are weaker: a paper cannot buy its way to the top on a dramatic claim. And a well-executed registry cohort lands above a badly executed randomised trial, which is the point of scoring execution rather than the design label.

A trial that demonstrated a benefit patients can feel sits above the same trial run to a decisive null. The margin is deliberately small. A null that rules out an important difference in both directions has answered the question, and it still outranks every observational study and every result that is statistically significant but too small to matter.

The score is deterministic, and every card shows the factors that moved it: the same reasoning the ranking used, not a post-hoc rationalisation. If you want to drive the arithmetic yourself, the scoring page runs this exact code in your browser.

Two things are deliberately absent. Citation counts: everything here is a week or two old, and at that age a citation count measures indexing speed, not importance. And reader-relevance signals like Canadian authorship or subspecialty: they say nothing about how good a paper is, so they feed the model that learns which papers actually get approved, never the score. Either way, heat is a screening tool, not a verdict: cold papers can still be great papers.

About the summaries. Summaries are generated by an AI model (Claude) from the paper's full text and reviewed by Pukhraj Gaheer, Medical Student, Queen's University before publishing. They are original paraphrases, not excerpts, and every card links to the actual paper via its DOI. Always read the full paper before citing it, and nothing on this site is medical advice.

The name. Orthopedics, and the talk around it: what gets argued about at rounds and forwarded on a Friday, which is more or less the whole job. Say it out loud and the three letters in the middle give away the rest: ortHOTalk, the week's hot topics. Not a coincidence.